DermTech and Harvard Publish Two Clinical Studies at IID
LA JOLLA, Calif.--(BUSINESS WIRE)--Jun 14, 2018--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting in Orlando, Fl. A real world clinical utility study, “Real-world experience and clinical utility of a non-invasive gene expression test for primary cutaneous melanoma and validation against high risk driver mutations in BRAF, NRAS and the TERT promoter,” demonstrated that combining gene expression and mutation analyses enhances the ability to non-invasively detect early melanoma.
The second clinical study “Non-invasive tape sampling reveals a type I interferon RNA signature in cutaneous lupus erythematosus that distinguishes affected from unaffected and healthy volunteer skin,” was conducted at Harvard Medical School and Brigham and Women’s Hospital. Type I interferon genes (IFN-I) are upregulated in skin lesions and blood from patients with cutaneous lupus erythematosus (CLE). This study assessed the feasibility of an adhesive tape device to collect RNA from affected and unaffected skin and its potential to detect gene expression differences between groups. The non-invasive technique demonstrated promise for the diagnosis, stratification and follow up of patients with CLE.
“Both studies demonstrate the potential of our adhesive patch skin sample collection platform to assess gene expression and mutations non-invasively in skin cancer as well as in inflammatory skin conditions,” said Dr. Burkhard Jansen, DermTech’s CMO.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180614006271/en/
CONTACT: DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA FLORIDA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY OTHER HEALTH MEDICAL SUPPLIES GENERAL HEALTH
SOURCE: DermTech, Inc.
Copyright Business Wire 2018.
PUB: 06/14/2018 05:21 PM/DISC: 06/14/2018 05:21 PM